{
    "nct_id": "NCT04405167",
    "official_title": "Phase 1 Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma",
    "inclusion_criteria": "1. Signed informed consent\n2. 18 years of age or older\n3. Multiple myeloma (MM) diagnosed according to IMWG criteria\n4. Measurable disease (this is defined differently in different arms)\n5. Multiple myeloma relapsed or refractory to treatment (this is defined differently in different arms)\n6. Meet certain clinical laboratory criteria\n7. ECOG performance status ≤2\n8. Life expectancy of at least 3 months\n9. For women of childbearing potential, a negative serum or urine pregnancy test prior to study treatment.\n10. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two methods of contraception one of which must be highly effective\n11. For men: agreement to use a barrier method of contraception for 1 month before start of study treatment, during the treatment period and for 6 months after the last dose of study treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Failure to have fully recovered (i.e. ≤ Grade 1 toxicity) from the effects of prior chemotherapy (except for alopecia)\n2. Active graft versus host disease\n3. Treatment with any of the following:\n\n   1. Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment\n   2. Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to the initiation of study treatment\n   3. Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter\n   4. Systemic corticosteroids >=10 mg prednisone or equivalent within 7 days prior to the initiation of study treatment\n   5. Radiotherapy within 7 days prior to initiating study treatment\n   6. Plasmapheresis within 4 weeks prior to the initiation of study treatment\n   7. Tasquinimod at any time\n4. Known central nervous system involvement by myeloma\n5. Diagnosis of smoldering multiple myeloma\n6. Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)\n7. Active plasma cell leukemia\n8. Symptomatic primary (AL) amyloidosis\n9. Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome\n10. Active other malignancy\n11. Major surgery within 4 weeks prior to initiating study treatment\n12. Evidence of severe or currently uncontrolled cardiovascular condition\n13. Ongoing or active systemic infection that requires systemic antibiotic or parenteral anti-infective therapy\n14. Active tuberculosis, active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive\n15. History of pancreatitis\n16. History of malabsorption or other condition that would interfere with absorption of study drugs\n17. Systemic treatment within 14 days prior to the initiation of study treatment with moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4 (CYP3A4)\n18. Need for ongoing therapy drug substances of narrow therapeutic range that are metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole, terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine)\n19. Need for ongoing therapy with drug substances of narrow therapeutic range metabolized mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron)\n20. Ongoing treatment with warfarin, unless the INR is <=3.0.\n21. For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis prophylaxis\n22. Peripheral neuropathy grade ≥2 (NCI-CTCAE)\n23. Known hypersensitivity to tasquinimod or any excipients in the study treatments\n24. Pregnant or nursing (lactating) women\n25. Any other condition that would, in the Investigator's judgment, contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures\n26. Prior inclusion in this study",
    "miscellaneous_criteria": ""
}